ATPase, class I, type 8B, member 1, ELISA Kit

Mouse Probable phospholipid-transporting ATPase IC (ATP8B1) ELISA kit; ATPIC; BRIC; FIC1; PFIC; PFIC1; E1-E2 ATPase; phospholipid-transporting ATPase IC; ATPase; class I; type 8B; member 1

For Research Use Only. Not for use in diagnostic procedures.

Store all reagents at 2-8 degree C

Select online data sheet information is drawn from bioinformatics databases, occasionally resulting in ambiguous or non-relevant product information. It is the responsibility of the customer to review, verify, and evaluate the information to make sure it matches their requirements before purchasing the kit. Our ELISA Kit assays are dynamic research tools and sometimes they may be updated and improved. If the format of this assay is important to you then please request the current manual or contact our technical support team with a presales inquiry before placing an order. We will confirm the current details of the assay. We cannot guarantee the sample manual posted online is the most current manual.

Small volumes of ATP8B1 elisa kit vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

MBS9329879 is a ready-to-use microwell, strip plate ELISA (enzyme-linked immunosorbent assay) Kit for analyzing the presence of the ATPase, class I, type 8B, member 1 (ATP8B1) ELISA Kit target analytes in biological samples. The concentration gradients of the kit standards or positive controls render a theoretical kit detection range in biological research samples containing ATP8B1. The ELISA analytical biochemical technique of the MBS9329879 kit is based on ATP8B1 antibody-ATP8B1 antigen interactions (immunosorbency) and an HRP colorimetric detection system to detect ATP8B1 antigen targets in samples. The ELISA Kit is designed to detect native, not recombinant, ATP8B1. Appropriate sample types may include undiluted body fluids and/or tissue homogenates, secretions. Quality control assays assessing reproducibility identified the intra-assay CV (%) and inter-assay CV(%).

143,798 Da

ATPase, class I, type 8B, member 1

phospholipid-transporting ATPase IC; ATPase 8B1, p type; ATPase B1, class I; aminophospholipid translocase; familial intrahepatic cholestasis type I; probable phospholipid-transporting ATPase IC; P4-ATPase flippase complex alpha subunit ATP8B1

Phospholipid-transporting ATPase IC

AT8B1_MOUSE

ATP8B1: May play a role in the transport of aminophospholipids from the outer to the inner leaflet of various membranes and the maintenance of asymmetric distribution of phospholipids in the canicular membrane. May have a role in transport of bile acids into the canaliculus, uptake of bile acids from intestinal contents into intestinal mucosa or both. Defects in ATP8B1 are the cause of progressive familial intrahepatic cholestasis type 1 (PFIC1); also known as Byler disease. PFIC1 is an autosomal recessive disorder, characterized by early infancy cholestasis, that may be initially episodic but progresses to malnutrition, growth retardation and end-stage liver disease before *****hood. Defects in ATP8B1 are the cause of benign recurrent intrahepatic cholestasis type 1 (BRIC1); also known as Summerskill syndrome. BRIC is characterized by intermittent episodes of cholestasis without progression to liver failure. There is initial elevation of serum bile acids, followed by cholestatic jaundice which generally spontaneously resolves after periods of weeks to months. The cholestatic attacks vary in severity and duration. Patients are asymptomatic between episodes, both clinically and biochemically. Defects in ATP8B1 can be associated with intrahepatic cholestasis of pregnancy (ICP); also known as pregnancy-related cholestasis. ICP is a multifactorial liver disorder of pregnancy. It presents during the second or, more commonly, the third trimestre of pregnancy with intense pruritus which becomes more severe with advancing gestation and cholestasis. Cholestasis results from abnormal biliary transport from the liver into the small intestine. ICP causes fetal distress, spontaneous premature delivery and intrauterine death. ICP patients have spontaneous and progressive disappearance of cholestasis after delivery. Belongs to the cation transport ATPase (P-type) (TC 3.A.3) family. Type IV subfamily.

Protein type: Transporter; Transporter, ion channel; Hydrolase; EC 3.6.3.1; Membrane protein, multi-pass; Membrane protein, integral

Cellular Component: Golgi apparatus; stereocilium; cell projection; membrane; brush border membrane; endoplasmic reticulum; apical plasma membrane; plasma membrane; integral to membrane

Molecular Function: phospholipid-translocating ATPase activity; hydrolase activity; metal ion binding; nucleotide binding; magnesium ion binding; ATP binding

Biological Process: phospholipid translocation; sensory perception of sound; vestibulocochlear nerve formation; inner ear receptor cell development; transport; bile acid metabolic process; multidrug transport; phospholipid transport; lipid transport; negative regulation of transcription, DNA-dependent; Golgi organization and biogenesis; regulation of microvillus biogenesis

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.